Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE | P12821 | 2/20 | 0.36 |
| ▸ | REN | P00797 | 2/20 | 0.36 |
| ▸ | BMP1 | P13497 | 3/20 | 0.33 |
| ▸ | FABP4 | P15090 | 8/20 | 0.31 |
| ▸ | FABP5 | Q01469 | 8/20 | 0.31 |
| ▸ | PDE4A | P27815 | 1/20 | 0.31 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.31 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.31 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.31 |
| ▸ | DPP4 | P27487 | 1/20 | 0.31 |
| ▸ | F2 | P00734 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21168275 | 0.98 | ACE (0.36) | ACERENBMP1FABP4FABP5 | |
| SCHEMBL21168356 | 0.98 | ACE (0.36) | ACERENBMP1FABP4FABP5 | |
| SCHEMBL21998929 | 0.95 | BMP1 (0.33) | ACERENBMP1FABP4FABP5 | |
| SCHEMBL21168299 | 0.94 | ACE (0.36) | ACERENBMP1FABP4FABP5 | |
| SCHEMBL31489982 | 0.94 | ACE (0.36) | ACERENBMP1FABP4FABP5 | |
| SCHEMBL21168320 | 0.94 | ACE (0.36) | ACERENBMP1FABP4FABP5 | |
| SCHEMBL23351265 | 0.94 | FABP4 (0.32) | ACEBMP1FABP4FABP5DPP4 | |
| SCHEMBL31490055 | 0.94 | ACE (0.36) | ACERENBMP1FABP4FABP5 | |
| SCHEMBL21168498 | 0.94 | ACE (0.34) | ACERENFABP4FABP5DPP4 | |
| SCHEMBL21168298 | 0.93 | BMP1 (0.33) | ACERENBMP1FABP4FABP5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220241248-A1 | COMBINATION OF SMALL MOLECULE CD-47 INHIBITORS WITH OTHER ANTI-CANCER AGENTS | AURIGENE ONCOLOGY LIMITED (IN) | 2022-08-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220241248-A1 | COMBINATION OF SMALL MOLECULE CD-47 INHIBITORS WITH OTHER ANTI-CANCER AGENTS | CD47, CD63, CD99 | ACE 4765/4885REN 4197/4885BMP1 2217/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.